McKesson reported robust fiscal second-quarter results, with consolidated revenue rising 8% year over year to $111.0 billion for the quarter ended September 30. Adjusted diluted earnings per share increased significantly by 18% to $11.68, while GAAP diluted earnings per share climbed to $10.44 from $8.92...
McKesson reported robust fiscal second-quarter results, driving a notable increase in its stock price. Consolidated revenue surged by 8 percent year over year to reach $111.0 billion, while adjusted earnings per diluted share climbed 18 percent to $11.68. This strong performance was fueled by growth...
McKesson Corporation delivered strong fourth-quarter financial results for fiscal 2026, reporting revenue of $96.3 billion, a 6% increase compared to the prior year, and adjusted earnings per share (EPS) of $11.69, up 16%. For the full fiscal year, revenue climbed 12% to $403.0 billion, while...
Bullish Signals
McKesson revenue grew 12% to $403B with adjusted profit rising 15%.
Adjusted EPS climbed 18% to $39.11, reflecting strong core operations.
McKesson Corporation is preparing to report its fiscal second-quarter 2027 earnings on Wednesday, November 4, 2026, following the market close. Analysts anticipate a significant beat in performance, with consensus estimates projecting earnings of $10.72 per share and revenue reaching $109.90 billion. These expected figures represent...
McKesson Corporation is preparing to release its fiscal second-quarter 2027 earnings report on Wednesday, November 4, following the market close. The pharmaceutical distributor enters this reporting period with a strong momentum from its first quarter, having previously exceeded Wall Street's earnings per share (EPS) estimates...
Bullish Signals
Beat EPS estimates for four consecutive quarters.
Q1 revenue hit $105.4B with adjusted EPS of $9.93.
Analysts forecast 8.4% YoY EPS growth to $10.69.
Management targets $44.20-$45.00 adjusted EPS for fiscal 2027.
McKesson Corporation announced a significant strategic investment of USD 1.4 billion to acquire a minority interest in Option Care Health, a move detailed in an agreement dated October 6, 2026. This transaction values the healthcare services provider at approximately USD 5.8 billion and establishes a...
Bullish Signals
Investing USD 1.4B in Option Care Health expansion.
Diversifying revenue into high-growth home health care.
McKesson Corporation reported a robust quarter ending August 5, 2026, with revenue reaching USD 105.38 billion and adjusted earnings per share (EPS) of USD 9.93. This performance exceeded the consensus estimate of USD 9.56, marking a year-over-year EPS increase of USD 1.67 compared to the...
Bullish Signals
McKesson beat analyst consensus estimates with adjusted EPS of USD 9.93 versus the expected USD 9.56 for the quarter ended August 5, 2026.
Revenue grew 7.7 percent year-over-year to reach USD 105.38 billion, demonstrating continued top-line expansion in the healthcare distribution sector.
The stock price rallied to USD 907.35, trading near its 52-week high of USD 999.00 and validating the market's positive reaction to the strong quarterly results.
Management provided FY 2027 EPS guidance of USD 44.2 to USD 45.0, which aligns well with external analyst expectations of USD 44.65 for the current fiscal year.
McKesson Corporation (MCK) is presented as a compelling long-term compounder with a share price of $763.91 as of June 23, 2026. Despite a recent decline from nearly $1,000 driven by a fiscal 2026 fourth-quarter revenue miss, the article argues the core investment thesis remains intact...
Bullish Signals
McKesson dominates pharmaceutical distribution with scale advantages.
$5.4B free cash flow generated in fiscal 2026.
Share count reduced over 60% via buybacks.
Onco segment grew revenue 31% and profit 53%.
70% return on invested capital shows efficiency.
$5B new share repurchase program authorized.
Bearish Signals
Missed Q4 2026 revenue target caused share price drop from ~$1,000.
Low 1.5% operating margins limit profitability vs higher-margin peers.
AdvisorShares Investments LLC reduced its position in McKesson Corporation (NYSE: MCK) by 8.4% in the first quarter, selling 782 shares to hold a remaining stake of 8,520 shares valued at $7.37 million. While AdvisorShares decreased its exposure, other institutional investors like Walter Public Investments Inc....
Bullish Signals
EPS beat estimates at $11.69 vs $11.56 consensus.
Revenue grew 6.0% YoY to $96.30 billion.
Walter Public Investments added 9,417 shares.
Astoria Portfolio Advisors increased stake by 5.8%.
UBS raised price target to $1,050 with buy rating.
Bearish Signals
Q1 revenue of $96.3B missed consensus of $101.35B.
CEO sold 8,463 shares worth $6.56M in one deal.
Insiders sold over 20,000 shares worth $15.5M recently.
Wall Street Zen downgraded stock from buy to hold.
JPMorgan lowered price target from $1,107 to $1,015.
McKesson Corporation (NYSE: MCK) is a leading diversified healthcare services company with a market capitalization of $87.88 billion, operating primarily in North American Pharmaceutical and Oncology & Multispecialty segments. Currently trading at $750.63, the stock has dipped slightly but maintains a significant growth potential highlighted...
Bullish Signals
Target price $941.40 suggests 25.41% upside from $750.63.
McKesson Corporation reported fourth-quarter fiscal 2026 adjusted earnings per share (EPS) of $11.69, surpassing the Zacks Consensus Estimate of $11.56 by 1.1% and showing a 15.5% year-over-year improvement in the bottom line. The enhanced EPS was primarily driven by strong operational performance across the business,...
Bullish Signals
EPS beat estimates with $11.69 quarterly adjusted results.
GAAP EPS rose 15.5% year-over-year to $13.71.
Projected fiscal 2026 adjusted EPS climbs 18.3% to $39.11.
Revenues forecast reach $403.43 billion, a 12.4% increase.
Oncology & Multispecialty segment revenue and profit surged 31% and 53%.
North American Pharmaceutical adjusted operating profit grew 11%.
Prescription Technology Solutions revenues increased 12% on demand.
Full-year EPS guidance raised to $43.80-$44.60 range.
Cash equivalents strengthened from $2.96B to $3.98B.
McKesson Corporation (NYSE: MCK) has announced plans to spin off its Medical-Surgical Solutions segment into a separate, independent company. This strategic move involves the separation of a specific business unit from the larger healthcare distribution conglomerate. As part of this restructuring initiative, Apollo-affiliated investors have...
Bullish Signals
Apollo investors commit US$1.25B to spun-off Medical-Surgical Solutions.
Spin-off enables focus on core distribution businesses.
McKesson Corporation announced a $2.25 billion acquisition of privately held Precision Medicine Group, a move designed to significantly strengthen its Oncology & Multispecialty segment. The deal integrates Precision Medicine's clinical research, laboratory testing, and commercialization services into McKesson's portfolio, aiming to enhance clinical trial execution...
Bullish Signals
McKesson is executing a disciplined capital recycling strategy by selling non-core assets like its medical-surgical solutions stake to fund high-growth investments.
The Oncology & Multispecialty segment, the target for integration, demonstrated exceptional growth with revenue jumping 33% to $14.2 billion in Q1 fiscal 2026.
The acquisition of Precision Medicine Group directly enhances McKesson's clinical research and commercialization services for biopharma customers.
Institutional confidence remains strong, evidenced by an increase in hedge fund holdings to 77 funds in Q2 2026 compared to 73 in the prior quarter.
Bearish Signals
The acquisition lacks a stated completion timeline, creating uncertainty regarding regulatory review duration and potential integration delays.
Analysts warn that the strategic rationale does not automatically guarantee financial payoff, requiring proof of scalability and synergy creation.
Integration risks are present as McKesson must effectively combine new clinical capabilities with its existing Oncology & Multispecialty operations.
The $2.25 billion deal is a modest bolt-on relative to the company's scale, limiting its potential for immediate transformative impact on overall earnings.
McKesson Corporation (NYSE: MCK) maintains a constructive analyst consensus ahead of its upcoming earnings season, with the majority of large Wall Street firms holding a 'Moderate Buy' rating. Data compiled by MarketBeat indicates an average price target of $960.53, suggesting approximately 29% upside from the...
Bullish Signals
Analysts maintain 'Moderate Buy' rating with $960.53 target.
Deutsche Bank reiterates buy with $875 price objective.
Apollo funds invest in high-growth Medical-Surgical Solutions unit.
McKesson (MCK) stock is currently trading at $785.43, which a valuation model suggests is undervalued by approximately 17.3% relative to a calculated fair value of $949.73. This assessment follows recent corporate developments including a US$2.25 billion senior secured term loan maturing in 2032, a minority...
Bullish Signals
McKesson trades at $785.43 vs $949.73 fair value, a 17.3% discount.
Secured US$2.25 billion term loan for growth without immediate dilution.
P/E ratio of 19.3x is below industry average of 23.2x.
8.87% one-year total shareholder return despite recent volatility.
Expansion into pharmacy management creates recurring revenue and margin visibility.
Bearish Signals
Stock down 14.66% in 90 days and 4.62% YTD.
Margin pressure from potential tighter drug price regulations.
Payers/PBMs may reduce reliance on traditional wholesalers.
McKesson Corp (NYSE:MCK) reported strong fiscal fourth-quarter results with full-year fiscal 2026 adjusted earnings per diluted share increasing by 18% to $39.11, driven primarily by growth in its oncology and multispecialty pharmaceutical segments. Consolidated revenue for the year reached $403 billion, up 12%, while operating...
McKesson's (MCK) valuation outlook has become mixed as analysts diverge on its risk-reward profile following a reduction in Simply Wall St's fair value estimate from US$990.87 to US$951.73, representing a 4% decrease. This adjustment aligns with a shifting landscape where bullish banks like Bank of...
Bullish Signals
BofA/Barclays lifted targets to US$1,040/US$1,050 in early 2026.
Biosimilars like Neulasta offer upside with seven launching soon.
William Blair initiated bullish coverage in April 2026.
Repurchased 2.5M shares for US$2,695.61m Jan-Mar 2026.
Increased buyback authorization to US$29,000m on April 29, 2026.
Bearish Signals
Fair value estimate trimmed 4% to US$951.73.
Revenue growth assumptions downgraded from 8.12% to 7.37%.
Future P/E multiple lowered from 23.04x to 20.49x.
McKesson Corporation (NYSE: MCK) reported a significant divergence between top-line growth and profitability in the most recent quarter, with revenue rising 7.70% to $410.98 billion while net earnings fell 21.70% to $4.59 billion. This decline in profit occurred despite the company maintaining its massive distribution...
Bullish Signals
Asset-light model enabled full equity retirement with massive market presence.
Durable moat as one of only three national drug distributors.
Holds $6.8B cash vs $6.85B expenses, funding buybacks easily.
McKesson (MCK) has regained investor attention following strategic portfolio changes, including its exit from Canada and Norway, and the planned spin-off of its Medical-Surgical unit. These moves are accompanied by a raised fiscal 2027 outlook, signaling a refocus on core growth drivers within the U.S....
Bullish Signals
McKesson has raised its fiscal 2027 outlook, signaling confidence in future earnings power and cash returns.
The company is increasing adoption of specialty and oncology pharmaceuticals to improve revenue mix quality.
Recent acquisitions of Core Ventures and PRISM Vision are expanding the provider network and service portfolio.
Strategic portfolio changes including exits from international markets aim to focus on core U.S. businesses.
The planned spin-off of the Medical-Surgical unit is intended to sharpen focus on higher-margin segments.
McKesson is pursuing disciplined share count reduction which supports a potential stock rerating.
Bearish Signals
Investors must monitor ongoing policy pressure on drug pricing which could impact revenue growth.
There is a risk that distributors or payers may bring more volume in-house, challenging McKesson's distribution thesis.
Hsbc Holdings PLC increased its stake in McKesson Corporation (NYSE: MCK) by 6.0% in the fourth quarter, purchasing an additional 15,594 shares to hold a total of 275,912 shares valued at approximately $226.8 million. This move represents a 0.23% ownership stake for Hsbc. Several other...
Bullish Signals
EPS beat estimates at $11.69 vs $11.56 consensus.
Rockefeller Capital increased position by 42.9%.
Multiple new institutional investors initiated positions.
UBS raised target to $1,050 with buy rating.
Quarterly dividend of $0.82 per share paid.
Bearish Signals
Revenue missed estimates at $96.30B vs $101.35B consensus.
Wall Street Zen downgraded stock from buy to hold.
JPMorgan lowered price target from $1,107 to $1,015.
CEO sold 8,463 shares worth $6.56 million in June.
Negative return on equity of 345.35% reported.
Insiders sold over 20,000 shares valued at $15.5M.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)